Hallucinogenic drugs have seen a major resurgence in scientific interest over the past decade. Psychedelics were extremely popular from the mid-1960s to the mid-1970s before they were criminalized. Even though people still consumed psychedelic drugs, albeit illegally, researchers were basically unable to study them for their potential benefits and risks. But with psychedelic interest among the scientific community surging, it has became clear that psychedelic drugs do have medical applications.
Clinical trials have found that hallucinogenic drugs have the potential to treat mental health conditions such as anxiety disorders, as well as eating disorders, when paired with conventional psychotherapy. Researchers have also found certain hallucinogenic drugs to be particularly effective at treating conditions such as post-traumatic stress disorder (PTSD) and major depressive syndrome, which are synonymous in the military veteran community.
However, federal law still prohibits the production, sale and consumption of psychedelics, meaning veterans who stand to benefit immensely from psychedelic-assisted therapy have to make do with alternatives that aren’t as safe or effective.
In the state of Georgia, officials are looking to remove the barriers that prevent military veterans from accessing much-needed psychedelic treatments. During a recent hearing on issues that face military veterans, state lawmakers discussed the potential effectiveness of using psychedelics such as psilocybin as a treatment for severe mental health conditions.
The House Defense and Veterans Affairs Committee heard testimonies from experts and people who had personally experienced psychedelics treatments, with the committee receiving information on emerging research indicating that psychedelics may have potential long-term benefits for mental conditions such as PTSD.
In March, the committee approved a bipartisan resolution calling for the formation of a House study committee to study the medical potential of psychedelic drugs. The committee would also be tasked with making recommendations for psychedelic reform based on its research into their therapeutic potential.
However, Committee chair Heath Clark said that with more than a dozen study committees being formed during the last legislative session, the psychedelics proposal was not enacted. Despite the legislation’s failure to cross the finish line, Clark said that it is crucial to have a discussion on the potential mental health benefits of psychedelic treatments for veterans. He said the hearing was essential because it would allow the committee to make recommendations on how to move forward with psychedelics, including providing funding to study how hallucinogenic drugs can benefit veterans.
Emory Healthcare Veterans Program medical director Boadie Dunlop was one of the witnesses who testified at the hearing, stating that he had recently co-published a study on psilocybin-assisted therapy that found definitive proof that psychedelic-assisted psychotherapy can be effective against psychiatric disorders.
Several other entities, such as Silo Pharma Inc. (OTCQB: SILO), are also focused on conducting studies aimed at developing novel ways to treat psychiatric and other indications using psychedelic compounds such as ketamine and psilocybin.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
